CTLA4 and non-small cell lung carcinoma: At present, clinically the most relevant therapeutic uses for anti-PD-(L)1-anti-CTLA-4 antibody combinations are in advanced melanoma [113], RCC [114], and NSCLC [115], anti-PD-(L)1 antibody -chemo in lung cancers [116,117] and triple-negative breast cancer [118], and anti-PD-(L)1 antibody -TKI in RCC [119].